| Name | Title | Contact Details |
|---|
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Today, the Cherokee Nation is the largest tribe in the United States with more than 390,000 tribal citizens worldwide.
Headquartered in Memphis, Tennessee, Accredo Health Group, Inc., provides specialty pharmacy and related services for patients with certain complex and chronic conditions through our unique Therapeutic Resource Centers. Accredo is a wholly owned subsidiary of Express Scripts. Accredo’s Therapeutic Resource Centers are segmented by therapy and provide targeted therapy management programs for the following therapeutic areas: Rheumatoid arthritis Multiple sclerosis Oncology Hepatitis C Immune disorders Pulmonary arterial hypertension Hemophilia Other specialty therapies with dedicated care teams (RSV, growth deficiencies, etc.) Our services cover the range of needs posed by specialty pharmacy care. Our pharmacists and other healthcare professionals talk frequently with patients over the phone, helping them follow their treatment and educating them about their condition. And our reimbursement specialists provide b enefits research services, with an explanation to the patient or patient’s caregiver of any financial responsibility he/she may have plus prior authorization determination.
Goodroot is a community of companies committed to reinventing healthcare one system at a time. Our mission is to reshape how our current system operates and make healthcare more affordable and more accessible for all. We develop and leverage businesses that not only improve the current state of healthcare delivery, but that also reform or replace the most critical parts of the system that are no longer working. Goodroot offers and sells the full range of products and services of all brands and companies underneath our umbrella to offer the most idealistic approach of capabilities for our clients. With a growing group of brands including RemedyOne, AlignRx, Penstock, Famulus, CoeoRx and ScholarScripts, Goodroot aims to helps everyone from pharmacy management to payment integrity and everyone in between.
Heart Force Medical Inc. (HFM), a private company, has invented and has patents pending for the digital Ballistocardiograph (dBG(TM)). The dBG 300, which is already approved in Canada and the United States, captures the movement of the heart during each cardiac cycle (heart beat). This movement (acceleration and force) is sensed by an accelerometer aligned to the three principal axes and displayed on a computer screen using HFM's proprietary software. Preliminary evaluation has determined that a 10-30 second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. The Heart Force dBG 300 device is a non-invasive, standalone, portable unit and contains sophisticated digital sensors and proprietary software.